Physician profile
Neil Maluste
NPI 1013358241
$3,341.73
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $799 · 2021: $1,412 · 2022: $635 · 2023: $246 · 2024: $33.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.12 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $339.89 | 2020-2022 | |
| Allergan, INC. | $244.54 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $232.11 | 2019-2021 | |
| Medtronic, INC. | $194.67 | 2023 | Linq II |
| Astrazeneca Pharmaceuticals LP | $165.82 | 2021 | |
| Biogen, INC. | $133.82 | 2020-2022 | |
| Genentech USA, INC. | $114.39 | 2019-2020 | |
| Eisai INC. | $108.15 | 2020-2021 | |
| Ucb, INC. | $100.13 | 2019-2022 | |
| Lilly USA, LLC | $99.60 | 2022 | |
| Tanabe Pharma America, INC. | $93.38 | 2020-2022 | |
| Lundbeck LLC | $91.58 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $88.65 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $81.02 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $77.68 | 2019-2022 | |
| Kyowa Kirin, INC. | $75.34 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $72.27 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $63.74 | 2020 | |
| Lantheus Medical Imaging, INC. | $59.64 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $47.33 | 2021 | |
| Merz North America, INC. | $36.55 | 2020 | |
| Mdd US Operations, LLC | $33.97 | 2022 | |
| Argenx US, INC. | $31.37 | 2022 | |
| Amgen INC. | $29.73 | 2019 | |
| Vertical Pharmaceuticals, LLC | $24.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.83 | 2021 | |
| Cala Health, INC. | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Maluste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.